Real stories of migraine-free days with Emgality
View efficacy results in patients with episodic or chronic migraine
Hear from real patients with episodic or chronic migrainea
aPatients were compensated for their time.
Patients with episodic migraine (4-14 migraine headache days [MHDs] per month)1,
Bonnie, a food enthusiast with migraine
Bonnie has had episodic migraine for nearly 15 years.
SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Tally Up helps empower patients to track and celebrate migraine-free days
The Tally Up Journal is a place where your patients can track migraine-free days. Patients also have Information Cards that they may share with friends who are interested in learning about Emgality.
You can request the Tally Up Journal by calling the Emgality Answers Center at 1-833-EMGALITY (1-833-364-2548).
SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.
SELECT IMPORTANT SAFETY INFORMATION
Adverse Reactions
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.
Start your patients on Emgality today
aGovernmental beneficiaries excluded.